Caroline Rousseau

Caroline Rousseau

Auto-generated profile, based on publicly available information

Caroline Rousseau

ICO-Gauducheau, CRCNA, UMR 892 Inserm, 6299 CNRS, Université de Nantes

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2006 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
CRC. Rousseau
C. Rousseau
EBE. Bourbouloux
E. Bourbouloux
Loic CampionLoic Campion
Loic Campion
NFN. Fleury
N. Fleury
BBB. Bridji
B. Bridji
MCM. Campone
M. Campone

10 February 2011 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
CRCaroline Rousseau
Caroline Rousseau
ADAnne Devillers
Anne Devillers
MCMario Campone
Mario Campone
Loic CampionLoic Campion
Loic Campion
LFLudovic Ferrer
Ludovic Ferrer
FKFrançoise Kraeber-Bodéré
Françoise Kraeber-Bodéré

1 September 2011 in EJNMMI Research
Verified
Journal Article
Open access
CRCaroline Rousseau
Caroline Rousseau
ARAnne Lise Ruellan
Anne Lise Ruellan
KBKarine Bernardeau
Karine Bernardeau
FKFrançoise Kraeber-Bodéré
Françoise Kraeber-Bodéré
SGSébastien GOUARD
Sébastien GOUARD
FDFrançois Davodeau
François Davodeau
Background: Overexpression of syndecan-1 (CD138) in breast carcinoma correlates with a poor prognosis and an aggressive phenotype. The objective of this study was to evaluate the potential of targeting CD138 by immuno-PET imaging and radioimmunotherapy (RIT) using the antihuman syndecan-1 B-B4 mAb radiolabeled with either 124I or 131I in nude mice engrafted with the triple-negative MDA-MB-468 breast cancer cell line. Method: The immunoreactivity of 125I-B-B4 (80%) was determined, and the affinity of 125I-B-B4 and the expression of CD138 on MDA-MB-468 was measured in vitro by Scatchard analysis. CD138 expression on established tumors was confirmed by immunohistochemistry. A biodistribution study was performed in mice with subcutaneous MDA-MB-468 and 125I-B-B4 at 4, 24, 48, 72, and 96 h after injection and compared with an isotype-matched control. Tumor uptake of B-B4 was evaluated in vivo by immuno-PET imaging using the 124I-B-B4 mAb. The maximum tolerated dose (MTD) was determined from mice treated with 131I-B-B4 and the RIT efficacy evaluated. Results: 125I-B-B4 affinity was in the nanomolar range (Kd = 4.39 ± 1.10 nM). CD138 expression on MDA-MB-468 cells was quite low (Bmax = 1.19 × 104 ± 9.27 × 102 epitopes/cell) but all expressed CD138 in vivo as determined by immunohistochemistry. The tumor uptake of 125I-B-B4 peaked at 14% injected dose (ID) per gram at 24 h and was higher than that of the isotype-matched control mAb (5% ID per gram at 24 h). Immuno-PET performed with 124I-B-B4 on tumor-bearing mice confirmed the specificity of B-B4 uptake and its retention within the tumor. The MTD was reached at 22.2 MBq. All mice treated with RIT (n = 8) as a single treatment at the MTD experienced a partial (n = 3) or complete (n = 5) response, with three of them remaining tumor-free 95 days after treatment. Conclusion: These results demonstrate that RIT with 131I-B-B4 could be considered for the treatment of metastatic triple-negative breast cancer that cannot benefit from hormone therapy or anti-Her2/neu immunotherapy. Immuno-PET for visualizing CD138-expressing tumors with 124I-B-B4 reinforces the interest of this mAb for diagnosis and quantitative imaging.

20 March 2010 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
APAmandine Pallardy
Amandine Pallardy
CBCaroline Bodet-Milin
Caroline Bodet-Milin
AOAurore Oudoux
Aurore Oudoux
Loic CampionLoic Campion
Loic Campion
EBEmmanuelle Bourbouloux
Emmanuelle Bourbouloux
CRCaroline Rousseau
Caroline Rousseau

1 January 2013 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
EFEric Frampas
Eric Frampas
CRCaroline Rousseau
Caroline Rousseau
CBCaroline Bodet-Milin
Caroline Bodet-Milin
JBJacques Barbet
Jacques Barbet
JCJean-Francois Chatal
Jean-Francois Chatal
FKFrançoise Kraeber-Bodéré
Françoise Kraeber-Bodéré
During the past two decades, considerable research has been devoted to radionuclide therapy using radiolabelled monoclonal antibodies and receptor binding agents. Conventional Radioimmunotherapy (RIT) is now an established and important tool in the treatment of hematologic malignancies such as Non-Hodgkin lymphoma. For solid malignancies, the efficacy of RIT has not been as successful due to lower radiosensitivity, difficult penetration of the antibody into the tumor and potential excessive radiation to normal tissues. Innovative approaches have been developed in order to enhance tumor absorbed dose while limiting toxicity to overcome the different limitations due to the tumor and host characteristics. Pretargeting techniques (pRIT) are a promising approach that consists of decoupling the delivery of a tumor monoclonal antibody (mAb) from the delivery of the radionuclide. This results in a much higher tumor-to-normal tissue ratio and is favorable for therapy as well and imaging. This includes various strategies based on avidin/streptavidin-biotin, DNA-complementary DNA and bispecific antibody-hapten bindings. PRIT continuously evolves with the investigation of new molecular constructs and the development of radiochemistry. Pharmacokinetics improve dosimetry depending on the radionuclides used (alpha, beta and Auger emitters) with prediction of tumor response and host toxicities. New constructs such as the Dock and Lock technology allow production of a variety of mABs directed against tumor-associated antigens. Survival benefit has already been shown in medullary thyroid carcinoma. Improvement in delivery of radioactivity to tumors with these pretargeting procedures associated with reduced hematologic toxicity will become the next generation of RIT. The following review addresses actual technical and clinical considerations and future development of pRIT.

5 May 2005 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
CRC. Rousseau
C. Rousseau
JCJ. M. Classe
J. M. Classe
Loic CampionLoic Campion
Loic Campion
CCC. Curtet
C. Curtet
FDF. Dravet
F. Dravet
IRI. Resche
I. Resche